Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease : Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)
المؤلفون المشاركون
Yokoyama, Hirokazu
Ebinuma, Hirotoshi
Oikawa, Yoichi
Shimada, Akira
Kikuchi, Masahiro
Irie, Junichiro
Itoh, Hiroshi
Tomita, Kengo
Saito, Hidetsugu
Hirose, Hiroshi
Kawai, Toshihide
Ojiro, Keisuke
Hirata, Takumi
Hibi, Toshifumi
المصدر
International Journal of Endocrinology
العدد
المجلد 2013، العدد 2013 (31 ديسمبر/كانون الأول 2013)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2013-08-13
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Aim.
This study compared the effects of telmisartan and losartan on nonalcoholic fatty liver disease (NAFLD) and biochemical markers of insulin resistance in hypertensive NAFLD patients with type 2 diabetes mellitus.
Methods.
This was a randomized, open-label, parallel-group comparison of therapy with telmisartan or losartan.
Nineteen hypertensive NAFLD patients with type 2 diabetes were randomly assigned to receive telmisartan at a dose of 20 mg once a day (n=12) or losartan at a dose of 50 mg once a day (n=7) for 12 months.
Body fat area as determined by CT scanning and hepatic fat content based on the liver-to-spleen (L/S) ratio, as well as several parameters of glycemic and lipid metabolism, were compared before and after 12 months.
Results.
The telmisartan group showed a significant decline in serum free fatty acid (FFA) level (from 0.87±0.26 to 0.59±0.22 mEq/L (mean ± SD), P=0.005) and a significant increase in L/S ratio (P=0.049) evaluated by CT scan, while these parameters were not changed in the losartan group.
Conclusion.
Although there was no significant difference in improvement in liver enzymes with telmisartan and losartan treatment in hypertensive NAFLD patients with type 2 diabetes after 12 months, it is suggested that telmisartan may exert beneficial effects by improving fatty liver.Erratum to “Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)”dx.doi.org/10.1155/2014/302602
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Hirata, Takumi& Tomita, Kengo& Kawai, Toshihide& Yokoyama, Hirokazu& Shimada, Akira& Kikuchi, Masahiro…[et al.]. 2013. Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease : Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). International Journal of Endocrinology،Vol. 2013, no. 2013, pp.1-9.
https://search.emarefa.net/detail/BIM-483000
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Hirata, Takumi…[et al.]. Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease : Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). International Journal of Endocrinology No. 2013 (2013), pp.1-9.
https://search.emarefa.net/detail/BIM-483000
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Hirata, Takumi& Tomita, Kengo& Kawai, Toshihide& Yokoyama, Hirokazu& Shimada, Akira& Kikuchi, Masahiro…[et al.]. Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease : Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). International Journal of Endocrinology. 2013. Vol. 2013, no. 2013, pp.1-9.
https://search.emarefa.net/detail/BIM-483000
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-483000
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر